MediPharm Labs appoints Warren Everitt to board of directors
by CM Staff
Warren Everitt brings manufacturing experience to the role at MediPharm Labs.
TORONTO — MediPharm Labs Corp. a pharmaceutical-quality cannabis extraction company, announced on Jan. 15, the appointment of Warren Everitt to its Board of Directors effective immediately.
Mr. Everitt joined MediPharm Labs in 2017 to establish the Company’s presence in the Australian market. As the founding CEO of Australia Pacific, he oversaw all aspects of the build out, start-up and commercialization of the GMP-certified extraction operation in Wonthaggi, Australia including licensing, factory design, finance, sales and marketing. Under his ongoing leadership, MediPharm Labs Australia has developed portfolio in the Asia Pacific and European medical and wellness cannabis markets.
“In reviewing the stewardship needs of a business that is rapidly expanding in the most promising cannabis markets worldwide, the Board concluded that Warren’s unique expertise, diverse perspectives and two decades of proven international experience would be highly accretive to MediPharm Labs’ corporate governance,” said Pat McCutcheon, Chairman, MediPharm Labs.
Before joining MediPharm Labs first as Managing Director, Australia, and subsequently being appointed CEO Australia Pacific, Mr. Everitt served in leadership roles at MarketOne International, a global consulting firm specializing in marketing and lead generation. Over eight years, he founded MarketOne’s Asia Pacific operations in Melbourne, Singapore, Bangalore and Tokyo. He is a graduate of Swinburne University of Technology (Bachelor of Computer Science) and Chisholm Institute in Melbourne. An Australian citizen, he currently resides in Melbourne.
“As pharmaceutical and manufacturing experts with two fully GMP certified platforms and a portfolio of enabling licences, MediPharm Labs is positioned for a new wave of growth as we open the door to sophisticated new pharma accounts and new medical and wellness-focused cannabis companies in emerging international jurisdictions,” said Mr. Everitt.
With Mr. Everitt’s appointment, MediPharm Labs’ Board of Directors will consist of eight members, five of whom are independent. The independent members include recognized experts in the pharmaceutical, pharmacy, consumer packaged goods, clinical research, finance and capital markets industries.
